Research Correspondence

DOI: 10.4244/EIJ-D-24-00355

A new resorbable magnesium scaffold (DREAMS 3G): 12-month vasomotion results from the BIOMAG-I first-in-human study

Michael Haude1, MD, PhD; Juan F. Iglesias2, MD; Hector M. Garcia-Garcia3, MD, PhD; Dimitrios Barlagiannis1, MD; Sophie Degrauwe2, MD; Gebremedhin Melaku3, MD; Solomon Beyene3, MD; Ron Waksman3, MD

BIOMAG-I is a European, multicentre first-in-human study assessing the safety and performance of a third-generation sirolimus-eluting resorbable magnesium scaffold (DREAMS 3G, commercial name Freesolve [Biotronik AG]). This is a next-generation scaffold with improved radial support and stability, a reduced strut thickness, and an increased size portfolio compared to its precursor DREAMS 2G (Biotronik), while the resorption period of 12 months has been maintained1. This substudy measures drug-induced vasomotion after complete scaffold resorption at 12 months.

The study was approved by the centres’ ethics committees, and all patients provided additional informed consent for vasomotion assessments in 2 study centres. Endothelial-dependent vasomotor reactivity was estimated by selectively infusing incremental doses of acetylcholine (ACh) into the target coronary artery: ACh1 (low dose) 0.36 μg/ml, ACh2 (middle dose) 3.6 μg/ml, and ACh3 (high dose) 18 μg/ml. Each ACh concentration was infused at a speed of 2 ml/min for 3 minutes. Contrast injection and angiographic images were taken at the end of the ACh infusion for each concentration.

When the maximum tolerated ACh dose was administered, an intracoronary bolus injection of nitroglycerine (NTG, 200 μg) was...

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 20 Number 17
Sep 2, 2024
Volume 20 Number 17
View full issue


Key metrics

Suggested by Cory

Editorial

10.4244/EIJ-E-24-00044 Sep 16, 2024
Serial intracoronary imaging to predict efficacy and safety of magnesium-based resorbable scaffolds
Räber L and Kakizaki R
free
Trending articles
310.93

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
172.13

Focus article

10.4244/EIJY19M08_01 Jan 17, 2020
EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update
Glikson M et al
free
91.35

State-of-the-Art Review

10.4244/EIJ-D-20-01296 Aug 27, 2021
Management of cardiogenic shock
Thiele H et al
free
76.25

State-of-the-Art

10.4244/EIJ-D-23-00840 Sep 2, 2024
Aortic regurgitation: from mechanisms to management
Baumbach A et al
free
56.65

Clinical research

10.4244/EIJ-D-20-01155 Oct 20, 2021
A deep learning algorithm for detecting acute myocardial infarction
Liu W et al
free
35

Original Research

10.4244/EIJ-D-25-00331 May 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved